Abstract:In the vast majority of malignancies, the p53 tumor suppressor pathway is compromised. In some cancer cells, high levels of MDM2 polyubiquitinate p53 and mark it for destruction, thereby leading to a corresponding downregulation of the protein. MDM2 interacts with p53 via its hydrophobic pocket, and chemical entities that block the dimerization of the protein–protein complex can restore p53 activity. Thus far, only a few chemical compounds have been reported as potent arsenals against p53-MDM2. The Protein Data Bank has crystallogaphic structures of MDM2 in complex with certain compounds. Herein, we have exploited one of the complexes in the identification of new p53-MDM2 antagonists using a hierarchical virtual screening technique. The initial stage was to compile a targeted library of structurally appropriate compounds related to a known effective inhibitor, Nutlin 2, from the PubChem database. The identified 57 compounds were subjected to virtual screening using molecular docking to discover inhibitors with high binding affinity for MDM2. Consequently, five compounds with higher binding affinity than the standard emerged as the most promising therapeutic candidates. When compared to Nutlin 2, four of the drug candidates (CID_140017825, CID_69844501, CID_22721108, and CID_22720965) demonstrated satisfactory pharmacokinetic and pharmacodynamic profiles. Finally, MD simulation of the dynamic behavior of lead-protein complexes reveals the stability of the complexes after a 100,000 ps simulation period. In particular, when compared to the other three leads, overall computational modeling found CID_140017825 to be the best pharmacological candidate. Following thorough experimental trials, it may emerge as a promising chemical entity for cancer therapy.

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Small Molecule Inhibitors of the P53-Mdm2

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Recent Advances of P53-Mdm2 Small Molecule Inhibitors (2011-Present).

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.

Small-molecule MDM2 inhibitors in clinical trials for cancer therapy

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

MDM2: current research status and prospects of tumor treatment

Insight on Heterocycles as p53‐MDM2 Protein‐Protein Interaction Inhibitors: Molecular Mechanism for p53 Activation

A small HDM2 antagonist peptide and a USP7 inhibitor synergistically inhibit the p53‐HDM2‐USP7 circuit

An update patent review of MDM2-p53 interaction inhibitors (2019-2023)

Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

D-Peptide Inhibitors of the P53-Mdm2 Interaction for Targeted Molecular Therapy of Malignant Neoplasms

Abstract 2785: Discovery of a Novel HDM2 Inhibitor with Potent in Vivo Anti-Tumor Activity

In Vitro Cytotoxicity and in Vivo Efficacy, Pharmacokinetics, and Metabolism of Pyrazole-Based Small Molecule Inhibitors of Mdm2/4–p53 Interaction